We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Blood Test Helps Identify Patients with Alzheimer's Associated Amyloid Pathology

By LabMedica International staff writers
Posted on 31 Jan 2025
Print article
Image: The U.S. FDA has granted Breakthrough Device Designation to the Access p‑Tau217/β-Amyloid 1-42 plasma ratio Test (Photo courtesy of Beckman Coulter)
Image: The U.S. FDA has granted Breakthrough Device Designation to the Access p‑Tau217/β-Amyloid 1-42 plasma ratio Test (Photo courtesy of Beckman Coulter)

Neurological diseases, such as Alzheimer's disease, are becoming an increasing cause of death and disability among older adults worldwide, posing significant challenges to healthcare systems. These conditions are complex and diverse, presenting a range of symptoms that complicate diagnosis. To address these challenges, a new blood test has been developed to help healthcare providers detect amyloid pathology associated with Alzheimer’s disease.

The Access p‑Tau217/β-Amyloid 1-42 plasma ratio, developed by Beckman Coulter Diagnostics (Brea, CA, USA), is a blood test that measures the ratio of phosphorylated tau protein (p-Tau217) and β‑Amyloid 1-42, both of which are key biomarkers involved in the neurodegenerative processes of Alzheimer's disease. This blood-based in vitro diagnostic (IVD) test is capable of quantifying these biomarkers in plasma, providing a non-invasive, accessible, and earlier method to detect Alzheimer’s-related pathology. Early detection is crucial for improving diagnosis, enabling timely interventions, and identifying patients for therapeutic trials, all of which can help accelerate progress in Alzheimer’s research and treatment. The Access p‑Tau217/β-Amyloid 1-42 plasma ratio has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

"We are honored to receive Breakthrough Device Designation from the U.S. FDA for our p‑Tau217/β-Amyloid 1-42 assay, a significant step forward in addressing the urgent need for earlier and more accurate detection of Amyloid pathology, a hallmark of Alzheimer's disease," said Kathleen Orland, Senior Vice President, General Manager, Clinical Chemistry and Immunoassay for Beckman Coulter Diagnostics. "This designation reflects the potential of our test to transform how Alzheimer's disease is diagnosed and managed, ultimately leading to improved outcomes for patients and families affected by this devastating disease."

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.